Patents by Inventor Ye E. Tian

Ye E. Tian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Rage fusion proteins
    Patent number: 7981423
    Abstract: Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies.
    Type: Grant
    Filed: August 3, 2005
    Date of Patent: July 19, 2011
    Assignee: Transtech Pharma, Inc.
    Inventors: Adnan M. M. Mjalli, Ye E. Tian, Jeffrey C. Webster, Robert Rothlein
  • Substituted heteroaryl derivatives, compositions, and methods of use
    Patent number: 7820704
    Abstract: The present invention provides substituted heteroaryl derivatives of Formula (I), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I), and methods of use in treating human or animal disorders. The compounds of the invention can be useful as inhibitors of action of AgRP on a melanocortin receptor and thus can be useful for the management, treatment, control, or the adjunct treatment of diseases which may be responsive to the modulation of melanocortin receptors including obesity-related disorders.
    Type: Grant
    Filed: April 20, 2005
    Date of Patent: October 26, 2010
    Assignee: TransTech Pharma, Inc.
    Inventors: Adnan M. M. Mjalli, Bapu R. Gaddam, Ghassan Qabaja, Govindan Subramanian, Jeff Zhu, John Dankwardt, Murty N. Arimilli, Robert C. Andrews, Samuel Victory, Ye E. Tian
  • Rage Fusion Proteins And Methods Of Use
    Publication number: 20090004190
    Abstract: Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies.
    Type: Application
    Filed: January 23, 2007
    Publication date: January 1, 2009
    Inventors: Adnan M.M. Mjalli, Jeffrey C. Webster, Robert Rothlein, Ye E. Tian